This company has been acquired
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
DICE Therapeutics Croissance future
Future contrôle des critères 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for DICE Therapeutics.
Informations clés
-22.3%
Taux de croissance des bénéfices
-14.8%
Taux de croissance du BPA
| Pharmaceuticals croissance des bénéfices | 24.1% |
| Taux de croissance des recettes | 86.8% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Good |
| Dernière mise à jour | 09 Aug 2023 |
Mises à jour récentes de la croissance future
Recent updates
We're Not Very Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Rate
May 14
DICE Therapeutics positive phase 1 data for psoriasis candidate leads shares 71% higher
Oct 11Here's Why We're Not Too Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Situation
Sep 11DICE Therapeutics GAAP EPS of -$0.58
Aug 11DICE Therapeutics initiated at buy at Wainwright on platform for small molecule drugs
Jul 18Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2025 | 2 | -224 | -161 | -205 | 8 |
| 12/31/2024 | N/A | -169 | -161 | -155 | 9 |
| 12/31/2023 | N/A | -140 | -116 | -109 | 9 |
| 6/30/2023 | N/A | -104 | -87 | -84 | N/A |
| 3/31/2023 | N/A | -91 | -75 | -73 | N/A |
| 12/31/2022 | N/A | -84 | -67 | -64 | N/A |
| 9/30/2022 | N/A | -77 | -63 | -61 | N/A |
| 6/30/2022 | N/A | -74 | -56 | -54 | N/A |
| 3/31/2022 | 1 | -59 | -46 | -45 | N/A |
| 12/31/2021 | 1 | -49 | -40 | -39 | N/A |
| 9/30/2021 | 1 | -40 | -31 | -30 | N/A |
| 6/30/2021 | 2 | -29 | -27 | -27 | N/A |
| 3/31/2021 | 1 | -27 | -24 | -24 | N/A |
| 12/31/2020 | 1 | -24 | -21 | -21 | N/A |
| 12/31/2019 | 6 | -13 | -17 | -16 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: DICE is forecast to remain unprofitable over the next 3 years.
Bénéfices vs marché: DICE is forecast to remain unprofitable over the next 3 years.
Croissance élevée des bénéfices: DICE is forecast to remain unprofitable over the next 3 years.
Chiffre d'affaires vs marché: DICE is forecast to have no revenue next year.
Croissance élevée des revenus: DICE is forecast to have no revenue next year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Insufficient data to determine if DICE's Return on Equity is forecast to be high in 3 years time